# FDA Decision Due on Atacicept for IgA Nephropathy

> fda · REPORTED · 2026-07-07

The FDA set a PDUFA target action date of July 7, 2026 for atacicept, Vera Therapeutics' dual BAFF/APRIL inhibitor for immunoglobulin A nephropathy, a prevalent cause of kidney failure. The decision represents a major regulatory catalyst for the company's lead asset.

About Vera Therapeutics: Vera Therapeutics is a clinical-stage biotech developing atacicept, a dual inhibitor of BAFF and APRIL, to treat IgA nephropathy and other antibody-mediated kidney diseases.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://www.biopharmawatch.com/PDUFA-calendar

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.